Portfolio
Latest Articles

PHASE II TRIALS

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Halucenex prepares for PTSD clinical trials

March 17th 2021

Halucenex prepares for PTSD clinical trials

Connect with us

EXPLORE

Finfeed Portfolio

Latest Articles

Archived Articles

About StocksDigital

PORTFOLIOS

Catalyst Hunter

STOCKS

FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS

CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY

The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).

© 2021 | AFSL (CAR No.433913)